AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$7.47
−$0.45 (−5.68%) 4:00 PM ET
After hours$7.47
$0.00 (0.00%) 6:33 PM ET
Prev closePrevC$7.92
OpenOpen$7.78
Day highHigh$7.87
Day lowLow$7.14
VolumeVol1,052,390
Avg volAvgVol1,063,471
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$307.55M
P/E ratio
-8.49
FY Revenue
$142.09M
EPS
-0.88
Gross Margin
74.98%
Sector
Healthcare
AI report sections
MIXED
RXST
RxSight, Inc.
No AI report section text found yet for this symbol.
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer
RxSight, Inc. announced preliminary 2025 full-year revenue of $134.5 million, exceeding guidance, driven by 109,615 Light Adjustable Lens procedures (12% increase YoY) and expansion of its installed base to 1,134 Light Delivery Devices. The company also appointed Mark Wilterding as Chief Financial Officer, bringing 25+ years of medtech financial leadership experience from Edwards Lifesciences.
Company exceeded revenue guidance ($134.5M vs. $125-130M guidance), achieved 12% YoY procedure volume growth, expanded installed base to 1,134 devices, and secured an experienced CFO from a major medtech company. CEO commentary reflects optimism about market stabilization, strong field engagement, and positioning for long-term growth.
NegativeBenzinga• Prnewswire
RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - RXST
DJS Law Group is investigating RxSight, Inc. for potential securities law violations after the company reported significant financial declines, including reduced sales of Light Delivery Devices and lowered annual financial guidance.
RXSTsecurities fraudfinancial investigationinvestor loss
Sentiment note
Company experienced a 38% stock price drop after reporting poor financial performance, declining sales metrics, and reduced annual guidance due to 'adoption challenges'
NegativeGlobeNewswire Inc.• James (Josh) Wilson
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight
Faruqi & Faruqi is investigating potential securities law violations by RxSight after the company reported significant sales declines and lowered financial guidance, causing its stock price to drop 37.8%.
Company reported significant declines in sales, lowered financial guidance by $42.5 million, experienced 'adoption challenges', and saw stock price drop 37.8% after revealing poor financial performance
NegativeGlobeNewswire Inc.• Rosen Law Firm
מחר המועד האחרון לתביעה נגד RXST: רוזן, יועץ למשקיעים מוביל, מעודד משקיעים ב- .RxSight, Inc עם הפסדים של יותר מ-100 אלף דולר להבטיח ייעוץ לפני המועד האחרון החשוב של 22 בספטמבר בתביעה ייצוגית בניירות ערך - RXST
Rosen Law Firm reminds RxSight investors who purchased securities between May 7, 2024 and July 8, 2025 about an upcoming September 22, 2025 deadline for a securities class action lawsuit, alleging the company misrepresented its growth potential and market performance.
The lawsuit alleges the company made false and misleading statements about its market growth, organizational performance, and customer adoption rates, suggesting systematic misrepresentation of its business metrics and potential
NegativeGlobeNewswire Inc.• Rosen Law Firm
RXST DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages RxSight, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities Class Action – RXST
Rosen Law Firm is alerting RxSight investors about a September 22, 2025 deadline for a securities class action lawsuit, alleging the company made false statements about customer adoption and growth metrics.
The lawsuit claims the company made materially false and misleading statements about its field organization performance, customer adoption rates, and growth model, suggesting potential financial misrepresentation
NegativeGlobeNewswire Inc.• Rosen Law Firm
מחר המועד האחרון לתביעה נגד REPL: רוזן, יועץ למשקיעים מיומן, מעודד את משקיעי Replimune Group, Inc. שצברו הפסדים של יותר מ- 100 אלף דולר להבטיח ייעוץ לפני המועד האחרון החשוב בתביעה ייצוגית בניירות ערך שהוגשה ראשונה על ידי המשרד – REPL
Rosen Law Firm alerts investors of Replimune Group and RxSight who suffered losses over $100,000 about an upcoming September 22, 2025 deadline for filing securities class action lawsuits related to allegedly misleading statements.
INVESTOR CLASS ACTION: RxSight, Inc. Investors are Reminded of the Ongoing Securities Fraud Lawsuit after Stock Plummeted 38% -- Contact BFA Law
RxSight, a medical device company specializing in light adjustable intraocular lenses, faces a securities fraud lawsuit after experiencing significant stock declines due to reported adoption challenges and market softening in its product line.
Stock price dropped 38% twice in 2025, company disclosed market adoption challenges, reduced revenue forecasts, and is now facing a securities fraud lawsuit alleging failure to disclose product utilization issues
NegativeBenzinga• Prnewswire
RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is pursuing a class action lawsuit against RxSight, Inc. for alleged securities fraud, claiming the company made false and misleading statements about its financial performance and product demand between November 2024 and July 2025.
The company is accused of making false statements about customer demand, experiencing adoption challenges, and being unlikely to achieve financial guidance, which suggests significant corporate governance and performance issues
NegativeGlobeNewswire Inc.• James (Josh) Wilson
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight
Faruqi & Faruqi is investigating potential securities claims against RxSight after the company reported significant sales declines and lowered financial guidance, causing its stock price to drop 37.8%.
RXSTsecurities litigationclass actionfinancial disclosurestock price drop
Sentiment note
Company reported significant declines in LDD sales, LAL utilization, and overall revenue, lowered full year guidance by $42.5 million, and experienced stock price drop of 37.8% after revealing 'adoption challenges'
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against RxSight, Inc. (RXST)
A securities class action lawsuit has been filed against RxSight, Inc. for allegedly making false statements and failing to disclose material adverse facts about the company's business during the period of November 7, 2024 to July 8, 2025.
The lawsuit alleges the company made misleading statements about its business, overstated product demand, was experiencing adoption challenges, and was unlikely to meet financial guidance, indicating significant potential corporate misconduct and financial misrepresentation
RXSIGHT DEADLINEALERT: Bragar Eagel & Squire, P.C. Reminds RXST Investors that a Class Action Lawsuit Has Been Filed Against RxSight, Inc. and Encourages Investors to Contact the Firm Before September 22nd
A class action lawsuit has been filed against RxSight alleging false statements about product demand and financial guidance, with stock price dropping 38% after revealing significant sales declines and adoption challenges.
Company reported significant declines in Light Delivery Device sales, lowered financial guidance by $42.5 million, and experienced substantial stock price drop of 38% due to alleged misleading statements about product demand and market adoption
RXST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
A class action lawsuit has been filed against RxSight alleging the company made false statements about its business performance, product demand, and financial guidance during the period of November 7, 2024 to July 8, 2025.
The lawsuit alleges multiple material misrepresentations including adoption challenges, overstated product demand, and inability to meet financial guidance, suggesting significant business performance issues
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
